Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Scholar Rock gets first FDA nod for rare muscle-wasting disease

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharma.economictimes.indiatimes.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

Scholar Rock received FDA approval for Isembyld, the first muscle-targeted therapy improving motor function in spinal muscular atrophy patients already treated with other therapies.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.

◆ ◆ The Wire takeaway

You have a new benchmark for muscle-targeted treatments that cleared FDA review. This opens doors for therapies focusing on motor function improvement in rare neuromuscular conditions.

◆ Coverage

9 sources · first reported 12 Sep 2026 · latest 14 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalrare-diseasespinal-muscular-atrophymuscle-wastingdrug-launch